Kian Sadeghi discusses Nucleus Genomics' growth targets compared to the largest existing whole genome sequencing databases.
Assertion Contradicted
Sadeghi: Nucleus is the first company to optimize embryos for IQ
“This is the first time a company has partnered with a couple who have optimized their embryos on the basis of intelligence.”
Opinion
Sadeghi: Patients, not doctors, should use genetic data to select embryos
“We believe that every piece of information from cancer to IQ to schizophrenia belongs very thoughtfully in the hands of the patient, and the patient is the one, not the doctor, that the patient is the one that should pick their embryo.”
Assertion Supported
Nucleus software analyzes embryo DNA to predict IQ, cancer risk, and traits
“So usually parents have a couple viable embryos, and now they can actually take the raw DNA files of them, upload to Nucleus, and we'll give you analysis on everything from cancers, to IQ, to eye color, to hair color, to schizophrenia risk.”
Prediction Not checkable as stated
Sadeghi: Falling IVF and sequencing costs will create genetically optimized children
“And so you're going to see the rapid decrease in cost of IVF combined with the rapid decrease in cost of sequencing A genome. These things are going to converge together to enable this just, this massive, massive new generation of parents having genetically op…”
Prediction Not checkable as stated
Sadeghi: Future reproductive genomics platforms will both sequence and edit DNA
“Because eventually, you're not just going to be sequencing and analyzing DNA, You'll also probably be editing it as well.”
Insight
Sadeghi: The medical distinction between genetic diseases and traits is arbitrary
“From our perspective as a company, there's really no difference between diseases and traits. It's a false line in the sand that was drawn.”